Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine
A Phase III, Randomized, Multinational Study, Double-blinded for the Immunogenicity and Consistency Evaluation of 3 Hib-MenCY-TT Vaccine Lots and Single-blinded and Controlled for the Evaluation of Safety and Immunogenicity of GSK Biologicals' Haemophilus Influenzae Type b and Neisseria Meningitidis Serogroups C and Y-tetanus Toxoid Conjugate Vaccine Combined (Hib-MenCY-TT) Compared to Monovalent Hib Vaccine in Healthy Infants at 2, 4, 6, and 12 to 15 Months of Age.
Sponsor: GlaxoSmithKline
A PHASE3 clinical study on Haemophilus Influenzae Type b and Neisseria Meningitidis, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 8 data snapshots since 2006. Infectious disease trials contribute critical data for public health response and treatment development.
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Sep 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Sep 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Feb 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amarillo, United States, Arkansas City, United States, Baltimore, United States, Bardstown, United States, Beaver Falls, United States, Birmingham, United States, Boardman, United States, Bossier City, United States, Boston, United States, Brainerd, United States and 73 more location s